A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

NEW YORK — Already in late-stage clinical trials, temtokibart, an interleukin (IL)-22 inhibitor, has demonstrated broad activity against multiple markers of inflammation, pruritus, and impaired ...

Olomorasib combined with pembrolizumab showed significant efficacy in KRAS G12C-mutant advanced NSCLC, with a 57.1% objective response rate and 11.8 months median progression-free survival. The study ...

Objective: This two-arm parallel randomized controlled trial with embedded N-of-1 analyses examined whether a digital intervention integrating gamification and telecoaching (Kiplin program) ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have each independently demonstrated significant cardiovascular benefits in ...

IAM1363 shown to be active across both HER2-wild-type and HER2-mutated cancers, and in multiple disease indications; responses seen in patients previously treated with T-DXd and tucatinib IAM1363 ...

Aedes (Stegomyia) aegypti (Linnaeus, 1762) plays a significant medical role as a vector of various arboviruses affecting humans, such as dengue (DENV), chikungunya (CHIKV), yellow fever (YFV), and ...